Defined medium for scalable production of stem cell-derived vesicles

A defined, xeno-free culture medium from Takara Bio Europe is opening new possibilities for large-scale production of extracellular vesicles (EVs) from human mesenchymal stem cells (MSCs) - a critical step toward developing next-generation cell-free therapies.

The Cellartis® MSC EV Wonder™ medium enables researchers to achieve up to nine times higher EV yields than conventional DMEM, while preserving key biological characteristics such as CD marker expression, morphology, and RNA cargo profiles.

As interest in MSC-derived EVs grows due to their regenerative and immunomodulatory potential, scalable and reproducible manufacturing has become a central challenge. Traditional culture systems often produce inconsistent vesicle quality or insufficient yields for translational research.

“Cellartis MSC EV Wonder was designed around a chemically defined supplement that eliminates variability and maintains essential MSC-EV features, ensuring reproducibility and simplifying the move toward GMP manufacturing,” explained Clemence Bonhomme, Scientist at Takara Bio Europe.

The medium’s phenol red–free formulation is compatible with Takara Bio’s Cellartis MSC Xeno-Free Culture System, allowing researchers to transition smoothly from MSC expansion to EV harvest.

“Reliable production of high-quality MSC-EVs has been a bottleneck for the field,” added Dr Tarik Hadi, Senior Market Strategy Manager. “With MSC EV Wonder, we’re providing a solution that strengthens quality control, streamlines workflows, and accelerates translation from discovery to clinical development.”

More information online